Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

IMAGENT

DIMYRISTOYL LECITHIN; PERFLEXANE

Standard Dose
0.92MG/VIAL;0.092MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview IMAGENT is listed in Drugs@FDA under application 021191 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DIMYRISTOYL LECITHIN; PERFLEXANE Form and strength INJECTABLE;INTRAVENOUS - 0.92MG/VIAL;0.092MG/VIAL Sponsor VESSELON SPV LLC Submission history Latest submission status date: 2004-04-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMAGENT is listed in Drugs@FDA under application 021191 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DIMYRISTOYL LECITHIN; PERFLEXANE Form and strength INJECTABLE;INTRAVENOUS - 0.92MG/VIAL;0.092MG/VIAL Sponsor VESSELON SPV LLC Submission history Latest submission status date: 2004-04-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.